KLOW Blend (BPC-157, TB-500, KPV, GHK-Cu)
Also known as: Klow Blend, KLOW, BPC-157, TB-500, KPV, GHK-Cu Blend
KLOW extends the GLOW concept by adding the anti-inflammatory tripeptide KPV to BPC-157, TB-500, and GHK-Cu. It is studied for recovery, gut and tissue healing, and skin quality, and its components are unapproved research peptides.
Last updated
Mechanism of Action
KLOW combines four peptides with complementary repair and anti-inflammatory actions. BPC-157 promotes VEGFR2- and nitric-oxide-driven angiogenesis and fibroblast migration; TB-500 sequesters G-actin to accelerate cell migration, vascularization, and wound closure; GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis and tissue-remodeling gene expression. KPV, the C-terminal tripeptide of alpha-MSH, exerts potent anti-inflammatory effects by inhibiting NF-kB and pro-inflammatory cytokine signaling, including in intestinal epithelium. Together the blend targets angiogenesis, matrix repair, and inflammation control simultaneously.
- Half-life
- Component-dependent: BPC-157, KPV, and GHK-Cu are short (minutes to hours), TB-500 functionally longer (days)
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Four-peptide blend targeting repair plus inflammation control
- KPV adds anti-inflammatory and gut-healing activity
- Studied for tendon, ligament, and soft-tissue recovery
- GHK-Cu supports collagen, elastin, and skin matrix
- Reported angiogenic and wound-healing effects
- Investigated for combined systemic, gut, and dermal endpoints
Potential Side Effects
- Injection-site redness, stinging, or irritation
- Possible headache, fatigue, or flushing
- Transient nausea or lightheadedness reported anecdotally
- Unknown long-term safety as an unapproved multi-peptide product
Common Dosing
For research use only and not medical advice: research blends are commonly reconstituted to deliver roughly 250-500 mcg BPC-157, 250-500 mcg TB-500, 250-500 mcg KPV, and 1-2 mg GHK-Cu per subcutaneous administration, typically several times weekly. No validated human dosing exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or prior malignancy due to angiogenic activity
- Copper sensitivity or Wilson's disease (GHK-Cu component)
- Pregnancy or breastfeeding
GLOW Blend (BPC-157, TB-500, GHK-Cu)
GLOW is a combination research blend of BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu studied for tissue repair, recovery, and skin and connective-tissue health. Each component is an unapproved research peptide.
BPC-157
A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.
TB-500
A synthetic version of the active region of Thymosin Beta-4, a naturally occurring peptide that regulates cell migration and tissue repair. Researched for recovery, flexibility, and wound healing.
KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH that exerts anti-inflammatory effects without pigmentary activity. It is studied for gut inflammation, wound healing, and skin conditions.
GHK-Cu
A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) widely researched for skin regeneration, collagen synthesis, and wound healing. Common in topical cosmetics.
- View
Pentadecapeptide BPC 157 and the central nervous system
2022
- View
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
2026
- View
Thymosin beta4 accelerates wound healing
1999
- View
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
2015
- View
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
2008